Neuronetics, Inc. (NASDAQ:STIM) CFO Sells $48,662.08 in Stock

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) CFO Stephen Furlong sold 14,836 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $3.28, for a total value of $48,662.08. Following the sale, the chief financial officer now directly owns 482,572 shares in the company, valued at $1,582,836.16. This trade represents a 2.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The stock was sold at an average price of $3.83, for a total value of $41,536.35.

Neuronetics Stock Up 11.8 %

Shares of NASDAQ STIM traded up $0.46 during midday trading on Friday, hitting $4.36. 3,032,060 shares of the company's stock were exchanged, compared to its average volume of 1,416,496. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics, Inc. has a twelve month low of $0.52 and a twelve month high of $5.07. The company has a market cap of $132.33 million, a PE ratio of -3.54 and a beta of 2.17. The firm's fifty day simple moving average is $2.20 and its 200-day simple moving average is $1.41.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Neuronetics by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock worth $506,000 after buying an additional 8,466 shares during the period. David J Yvars Group increased its position in Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company's stock worth $75,000 after buying an additional 14,825 shares during the period. Tradewinds LLC. acquired a new position in Neuronetics during the fourth quarter worth approximately $32,000. XTX Topco Ltd acquired a new position in Neuronetics during the fourth quarter worth approximately $49,000. Finally, GSA Capital Partners LLP increased its position in Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company's stock worth $60,000 after buying an additional 30,837 shares during the period. Institutional investors and hedge funds own 53.59% of the company's stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.